Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed's Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss' presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Bliss will provide an overview of the Company's clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.

Mr. Bliss's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical compa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 ... Repair Market by Product (Mesh/Tissue patch, Allograft, Xenograft, Suture ... Orthopedic, Skin, Dental, Vaginal, Breast augmentation) - Global Forecast ... Market is expected to reach $14.7 Billion in 2019 ... of 7.5% from 2014 to 2019. ...
(Date:3/6/2015)... N.Y. , March 6, 2015 BioSpecifics ... company developing first in class collagenase-based products marketed as ... the U.S. and XIAPEX ®  in the EU, announced ... live audio webcast at 8:30 a.m. ET on Friday, ... full year 2014 financial results and provide a corporate ...
(Date:3/6/2015)... Wash. , March 6, 2015   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... the Company,s fourth quarter and full year 2014 financial results ... that the Company will host a conference call and ...
(Date:3/5/2015)... , March 5, 2015   HX360 ... semi-finalists in the HX360 Innovation Challenge competition. ... will compete to be chosen as one of four ... of senior health system executives and venture capitalists during ... Innovation Challenge takes place at the 2015 HIMSS Annual ...
Breaking Biology Technology:Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4
... Bedside Detection of Ischemic ... Infarction (Heart Attack), TEL AVIV, Israel, February 26 ... develops and markets systems for,non-invasive diagnosis and monitoring of ... using its proprietary,HyperQ technology in resting conditions., The ...
... today announced the,appointment of Douglas W. Axelrod, M.D., ... Development., Axelrod joins Ambrx after a productive ... Pharmaceuticals. Most recently, he served as,Vice President of ... he accelerated the discovery process, improved the,discovery to ...
... to join the Company, NATICK, Mass., Feb. 26 ... that Jay J. Schnitzer, M.D., Ph.D.,will be joining the ... will serve as Vice President and Associate Chief Medical,Officer, ... the Chief,Medical and Scientific Officer, Dr. Donald S. Baim, ...
Cached Biology Technology:BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study 2Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development 2Boston Scientific Announces Addition to Clinical Sciences Organization 2Boston Scientific Announces Addition to Clinical Sciences Organization 3Boston Scientific Announces Addition to Clinical Sciences Organization 4
(Date:2/5/2015)... , January 28, 2015 New ... Size And Segment Forecasts To 2020 has Been Added ... camera market is expected to reach USD 5.10 billion ... View Research, Inc. IR cameras help identify the site ... expected to witness surging demand in medical imaging applications. ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... DALLAS, April 3, 2012 /PRNewswire-iReach/ -- FirstMark today ... Regional Sales Manager for the Southeast region of the United ... primary role will be to drive growth and awareness for ... test that distinguishes the top 5 percent of suspected or ...
... EAST LANSING, Mich. For children with autism, being ... to increase the severity of their symptoms, according to ... autistic children who were born either preterm or post-term ... children born on time, revealed the study by Tammy ...
... Rodney Howell, MD, FACMG, is the recipient of the 2012 ... Dr. Howell is Professor of Pediatrics and Chairman Emeritus ... Miami. Dr. Howell, president of the American College of ... work in the field of pediatrics and genetic research and ...
Cached Biology News:FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager 2Autistic kids born preterm, post-term have more severe symptoms 2Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 2Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 3Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 4
... This kit is designed for the fast ... vector plasmids at any position (for the ... loxP-PGK-gb2-neo-loxP cassette is designed to allow neomycin ... cells. It combines a prokaryotic promoter (gb2) ...
... RoboSep is the first instrument to offer true ... EasySep technology to isolate cells by either positive ... up to 4 samples at one time. RoboSep ... The intuitive graphical user interface makes it simple ...
Plasmid expressing the LacZ reporter gene....
Plasmid expressing Zeocin resistance gene....
Biology Products: